GLP-1 类似物 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-07-29. Numbers and descriptions here follow the published literature rather than marketing material.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | free base, without counter-ion |
| Molecular weight | About 4114 Da | peptide backbone plus attached lipid chain |
| Plasma half-life | About 165 hours | supports once-weekly dosing in humans |
| Plasma protein binding | Greater than 99 percent | attributed mainly to serum albumin |
| Receptor target | GLP-1 receptor | Gs-coupled, raises intracellular cyclic AMP |
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。
该分子作为 GLP-1 受体的选择性激动剂发挥作用，受体属于 B 类 G 蛋白偶联受体家族，激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞，信号促进葡萄糖依赖性的胰岛素释放，血糖偏低时该作用明显减弱。在胰岛 α 细胞，胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达，相应信号参与食欲调节以及胃排空速率的降低。
皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
By replacing certain parts of the internal design, Valve was able to reduce the production cost. The previous version had used a sync blinker system, which caused interference between beacons placed in the same setup. By changing to a "sync-on-beam" design, data encoded on sweeps, resolved the interference issue. Dropping one of the rotators to establish two beams from one light, meant that the required internal cabling of the beacons was simplified. Valve's changes to the first revision widened field of view and facilitated an easier setup for the end user.
In 2012, the U.S. Justice Department announced GlaxoSmithKline had agreed to plead guilty and pay a $3 billion fine, in part for withholding the results of two studies of the cardiovascular safety of Avandia between 2001 and 2007. The settlement stems from claims made by four employees of GlaxoSmithKline, including a former senior marketing development manager for the company and a regional vice president, who tipped off the government about a range of improper practices from the late 1990s to the mid-2000s.
The majority of π-helices are only 7 residues in length and do adopt regularly repeating (φ, ψ) dihedral angles throughout the entire structure like that of α-helices or β-sheets. Because of this, textbooks that provide single dihedral values for all residues in the π-helix are misleading. Some generalizations can be made, however. When the first and last residue pairs are excluded, dihedral angles exist such that the ψ dihedral angle of one residue and the φ dihedral angle of the next residue sum to roughly −125°. The first and last residue pairs sum to −95° and −105°, respectively. For comparison, the sum of the dihedral angles for a 310 helix is roughly −75°, whereas that for the α-helix is roughly −105°. Proline is often seen immediately following the end of π-helices. The general formula for the rotation angle Ω per residue of any polypeptide helix with trans isomers is given by the equation
which is a Bernoulli equation valid also for unsteady—or time dependent—flows. Here ∂φ/∂t denotes the partial derivative of the velocity potential φ with respect to time t, and v = |∇φ| is the flow speed. The function f(t) depends only on time and not on position in the fluid. As a result, the Bernoulli equation at some moment t applies in the whole fluid domain. This is also true for the special case of a steady irrotational flow, in which case f and ∂φ/∂t are constants so equation (A) can be applied in every point of the fluid domain. Further f(t) can be made equal to zero by incorporating it into the velocity potential using the transformation:
According to contemporaries:most of the farmers, who are not sufficiently educated, follow mechanically and without reflection, the practice of their small township or the method of their old relatives. A new culture would require a tiring study. [...] But in vain would one cultivate, in vain would one multiply this salutary commodity, if the people themselves, if the poorest citizens, stubborn of an absurd prejudice, refused, disdained to consume it. We have seen them, in times of the cruellest famine, rejecting the potato with fury, and shouting that we wanted to poison them. (French: la plupart des cultivateurs, trop peu instruits, suivent machinalement et sans réflexions, la pratique de leur petit canton ou la méthode de leurs vieux parens. Une nouvelle culture leur demanderoit une étude fatigante. […] Mais en vain cultiveroit-on, en vain multiplieroit-on cette denrée salutaire, si le peuple lui-même, si les citoyens les plus pauvres, entêtés d'un préjugé absurde, refusoient, dédaignoient de la consommer. On les a vus, dans les temps de la plus cruelle disette, repousser avec fureur la pomme de terre, et crier qu'on les vouloit empoisonner.)
Sources: en.wikipedia.org
==== Rivaroxaban binding to factor Xa ==== Rivaroxaban binding to FXa is mediated through two hydrogen bonds to the amino acid Gly-219. These two hydrogen bonds serve an important role directing the drug into the S1 and S4 subsites of FXa. The first hydrogen bond is a strong interaction which comes from the carbonyl oxygen of the oxazolidinone core of rivaroxaban. The second hydrogen bond is a weaker interaction and comes from the amino group of the clorothiophene carboxamide moiety. These two hydrogen bonds result in the drug forming an L-shape and fits in the S1 and S4 pockets. The amino acids residues Phe-174, Tyr-99, and Trp-215 form a narrow hydrophobic channel that is the S4 binding pocket. The morpholinone part of rivaroxaban is “sandwiched” between amino acids Tyr-99 and Phe-174 and the aryl ring of rivaroxaban is oriented perpendicularly across Trp-215. The morpholinone carbonyl group does not have a direct interaction to the FXa backbone, instead, it contributes to a planarization of the morpholinone ring and therefore supports rivaroxaban to be sandwiched between the two amino acids.
Portugal's territory comprises mainland Portugal and the Azores and Madeira archipelagos. The mainland, commonly referred to as Continental Portugal, is located in the southwest of the Iberian Peninsula in Southwestern Europe, while Madeira and the Azores lie in the Atlantic Ocean. Portugal's land area is 92,225 km2 (35,608 sq mi), although Portuguese law defines the country's size as 156,597 km2 (60,462 sq mi) which includes about 64,000 km2 (24,711 sq mi) of ocean waters. Portugal's exclusive economic zone extends 1,727,408 km2 (666,956 mi2), making it one of the largest in the European Union. The country is over two-thirds wilderness, almost one-fourth agricultural, and the remainder human settlements. Portugal's highest point is the summit of Mount Pico, located on Pico Island in the Azores, which rises to an elevation of 2,351 m (7,713 ft) above sea level. Portugal can be divided into four morphostructural units: the Hesperian Massif, which occupies most of mainland Portugal; the sedimentary borderlands of the massif, forming the Lusitanian and Algarve basins; the Lower Tagus and Alvalade sedimentary basins; and the volcanic submarine ranges that form the Azores and Madeira. Its geological and geomorphological features are largely the product of the Variscan, responsible for the formation of the Hesperian Massif, and later the Tethys–Atlantic cycle, responsible for the remaining units.
21 April – Mark Menzies quits the Conservative Party and says he will stand down from Parliament at the next election. Robin Swann, who is the perspective Ulster Unionist candidate for South Antrim, announces he will step down from his post as Northern Ireland's Health Minister once the general election campaign begins. 22 April – Parliament passes the Safety of Rwanda Bill, with plans to deport the first asylum seekers to Kigali in July. Two men, including a parliamentary researcher, are charged with spying for China after providing information that could be "useful to an enemy". Conservative councillor Richard Solesbury-Timms, who represents Middleton Cheney on West Northamptonshire Council, leaves the party to sit as an independent citing the party's dealing with allegations against the council leader. 23 April – Patrick Harvie says he will resign as co-leader of the Scottish Greens if the party votes to end its coalition agreement with the SNP. Alliance Party MLA Patrick Brown resigns his South Down seat in the Northern Ireland Assembly, citing personal reasons for doing so. 24 April – Rishi Sunak vows to increase UK defence spending to 2.5% of GDP by 2030. Labour unveils its plans for improvements to train services, which include automatic refunds for delays, a "best price" guarantee and improved internet coverage. Jeffrey Donaldson appears at Newry Magistrates' Court to face charges of historic child abuse. Johnny Timpson, the UK's inaugural disability ambassador, resigns over the UK government's policy of clawing back benefit overpayment.
During and after the end of World War II, scientists working on the Manhattan Project and other nuclear weapons research projects conducted studies of the effects of plutonium on laboratory animals and human subjects. Animal studies found that a few milligrams of plutonium per kg of tissue is a lethal dose. For human subjects, this involved injecting solutions typically containing 5 micrograms (μg) of plutonium into hospital patients thought to be either terminally ill, or to have a life expectancy of less than ten years either due to age or chronic disease. This was reduced to 1 μg in July 1945 after animal studies found that the way plutonium distributes itself in bones is more dangerous than radium. Most of the subjects, Eileen Welsome says, were poor, powerless, and sick. In 1945–47, eighteen human test subjects were injected with plutonium without informed consent. The tests were used to create diagnostic tools to determine the uptake of plutonium in the body in order to develop safety standards for working with plutonium. Ebb Cade was an unwilling participant in medical experiments that involved injection of 4.7 μg of plutonium on April 10, 1945, at Oak Ridge, Tennessee. This experiment was under the supervision of Harold Hodge. Other experiments directed by the United States Atomic Energy Commission and the Manhattan Project continued into the 1970s. The Plutonium Files chronicles the lives of the subjects of the secret program by naming each person involved and discussing the ethical and medical research conducted in secret by the scientists and doctors.
==== Italy, South Leigh and Prague ==== The following year, in April 1947, the Thomases travelled to Italy, after Thomas had been awarded a Society of Authors scholarship. They stayed first in villas near Rapallo and then Florence, before moving to a hotel in Rio Marina on the island of Elba. On their return, Thomas and family moved, in September 1947, into the Manor House in South Leigh, just west of Oxford, purchased and rented to Thomas for £1 per week by Margaret Taylor. He continued with his work for the BBC, completed a number of film scripts and worked further on his ideas for Under Milk Wood, including a discussion in late 1947 of The Village of the Mad (as the play was then called) with the BBC producer Philip Burton. He later recalled that, during the meeting, Thomas had discussed his ideas for having a blind narrator, an organist who played for a dog and two lovers who wrote to each other every day but never met. In March 1949 Thomas travelled to Prague. He had been invited by the Czech government to attend the inauguration of the Czechoslovak Writers' Union. Jiřina Hauková, who had previously published translations of some of Thomas's poems, was his guide and interpreter. In her memoir, Hauková recalls that at a party in Prague, Thomas "narrated the first version of his radio play Under Milk Wood." She describes how he outlined the plot about a town that was declared insane, mentioning the organist who played for sheep and goats and the baker with two wives.
Sources: en.wikipedia.org
== Bibliography == Brock, Sebastian P. (1987). "North Mesopotamia in the late Seventh Century: Book XV of John Bar Penkāyē's Rīš Mellē". Jerusalem Studies in Arabic and Islam. 9: 51–75. ISSN 0334-4118. Crone, Patricia (1980). Slaves on Horses: The Evolution of the Islamic Polity (1980 ed.). Cambridge: Cambridge University Press. p. 93. ISBN 978-0521229616. Donner, Fred M. (2010). Muhammad and the Believers. Cambridge: The Belknap Press of Harvard University Press. ISBN 978-0-674-05097-6. Gibb, H. A. R. (2013) [1923]. The Arab Conquests in Central Asia. Read Books. ISBN 1-4067-5239-8. Gibb, H. A. R. (2007). The Arab Conquests in Central Asia. Read Books. ISBN 978-1-4067-5239-7. reprinted from the 1923 edition, published by the Royal Asiatic Society OCLC 474026895. Hasson, I. (2002). "Ziyād b. Abiḥī". In Bearman, P. J.; Bianquis, Th.; Bosworth, C. E.; van Donzel, E.; Heinrichs, W. P. (eds.). The Encyclopedia of Islam. Vol. XI: W–Z (new ed.). Leiden and New York: Brill. pp. 519–522. ISBN 90-04-12756-9. Kennedy, Hugh (2001). The Armies of the Caliphs: Military and Society in the Early Islamic State. London and New York: Routledge. ISBN 0-415-25093-5. Kennedy, Hugh (2004) [1986]. The Prophet and the Age of the Caliphates: The Islamic Near East from the 6th to the 11th Century (Second ed.). Harlow: Longman. ISBN 978-0-582-40525-7. Madelung, Wifred (October 1981). "ʿAbd Allāh b. al-Zubayr and the Mahdi". Journal of Near Eastern Studies. 4 (1): 291–305. ISSN 0022-2968. JSTOR 544603. Robinson, C. F. (2000). "ʿUbayd Allāh b. Ziyād". In Bearman, P. J.; Bianquis, Th.; Bosworth, C.
The study of these structures and related self-organized systems is known as "chemobrionics", an emerging interdisciplinary field that integrates the concepts of physics, chemistry, materials science, biology and complex systems science to investigate reaction-diffusion-driven pattern formation. The term chemobrionics derives from "chemo" and the Greek word bruein ("to grow or enlarge"), referring to the osmotically driven growth of chemical gardens and related self-organized inorganic systems.
== History == The first education board to be set up in India was the United Provinces Board of High School and Intermediate Education in 1921, which was under the jurisdiction of Rajputana, Gwalior and Central India. In 1929, In response to the representation made by the Government of United Provinces, the Government of India suggested to set up a joint board for all the areas and it was named as the Board of High School and Intermediate Education Rajputana. This included Gwalior, Ajmer, Central India and Merwara. In 1962, The board was reconstituted to extend its services, merging with the Delhi Board of Higher Secondary Education and thus it became the Central Board of Secondary Education.
== Chemistry == Pure acetylcysteine is in a solid state at room temperature, appearing as a white crystalline powder or granules. The solid form of acetylcysteine is stable under normal conditions, but it can undergo oxidation if exposed to air or moisture over time, leading to the formation of its dimeric form, diacetylcysteine, which can have different properties. Acetylcysteine is highly hygroscopic, i.e., it absorbs moisture if exposed to open air. Acetylcysteine can sometimes appear as a light yellow cast powder instead of pure white due to oxidation. The sulfur-containing amino acids, like cysteine, are more easily oxidized than other amino acids. When exposed to air or moisture, acetylcysteine can oxidize, leading to a slight yellowish tint. Acetylcysteine in a form of a white or white with light yellow cast powder has a pKa of 3.14 (carboxyl group) and 9.5 (thiol) at 30 °C. N-acetyl-L-cysteine is soluble in water and alcohol, and practically insoluble in chloroform and ether. Acetylcysteine dissolves readily in water, forming a colorless solution. The pH of a 1% acetylcysteine solution in water typically ranges between 2.0 and 2.8. Solutions with higher concentrations of acetylcysteine have lower pH. Aqueous solutions of acetylcysteine are compatible with 0.9% sodium chloride solution; compatibility with 5% and 10% glucose solutions is also good. As for photochemical stability, acetylcysteine in dry powder form is relatively stable and does not degrade quickly when exposed to light, but in aqueous solution, acetylcysteine can degrade when exposed to sunlight.
=== Names === Flunitrazepam is marketed under many brand names in the countries where it is legal. It also has many street names, including "roofie" and "ruffie". It is also known as Circles, Forget Me Pill, La Rocha, Lunch Money Drug, Mexican Valium, Pingus, R2, and Roach 2.
Sources: en.wikipedia.org
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.
Albumin is the most abundant protein in plasma and carries molecules that bear fatty-acid chains. Binding shields the peptide from renal filtration and from peptidases, keeping a circulating reservoir. Slow release from this reservoir produces sustained receptor occupancy and supports infrequent dosing.
The insulinotropic effect is glucose-dependent, meaning secretion increases mainly when glucose is elevated. This property is often described as lowering the chance of hypoglycaemia when the compound is used alone. Other glucose-lowering agents used at the same time can still cause low blood glucose.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.